Home › Follicular Lymphoma › NCT04160910
5HTP Regulation Of Asthma In Children
Who can join
Ages 8 to 18 · All sexes
Full eligibility criteria
Inclusion Criteria: * Age 8-18 Years of Age * Mild to Moderate Asthma based on ATS guidelines * Positive Allergy Test (positive skin or serum IgE) * Weight ≥ 70 lbs (32 kg) * CES-DC cut-off ≥ 15 (total score range is 0 to 60) or SCARED cut-off * 25 (total score range is 0 to 142) * Ability to comply with study visits and study procedures * Informed Consent by participant and if applicable the parent or legal guardian Exclusion Criteria: * Currently taking a SSRI * Taking a leukotriene inhibitor (montelukast, Zileuton) * Severe Asthma Based on ATS Guidelines * Taking a biologic medication (omalizumab, mepolizumab, benralizumab, dupilumab) * Medical History of Adverse Reaction to 5HTP * Physical findings that would compromise the safety of the study or the quality of the study data
About the study
The purpose of this study is to learn more about if taking a supplement called 5-hydroxytryptophan (5HTP) can improve breathing and anxiety symptoms related to asthma. To help learn more subjects will either be assigned to a group that is taking the supplement (5HTP) or a group that is taking a placebo. This will be decided randomly. Later in the study subjects will crossover to the other group.There are 5 study visits over the course of about 12 weeks.
What is being tested
- 5-Hydroxytryptophan (drug)
- Placebo (drug)
Sponsor: Indiana University · Participants: 20 · Started: Feb 11, 2021
Contact the study team
- Kirsten Kloepfer, MD · Phone: (317) 278-7860
- Patrick Campbell, BS · Phone: (317) 278-7117
Official record on ClinicalTrials.gov — NCT04160910
Locations in the U.S.
| Indiana | Indiana University, Indianapolis |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.